January 25th 2023
Patients with breast cancer who carry BRCA1, BRCA2, CHEK2, or PALB2 germline pathogenic variants may be at a greater risk for contralateral breast cancer and may benefit from enhanced surveillance and risk-reduction strategies.
Podsada Discusses Biomarker Testing and ADC Therapies in Breast CancerAugust 16th 2022
The growing availability of biomarkers has led to the advent of more targeted therapies such as the antibody-drug conjugates (ADCs) fam-trastuzumab deruxtecan-nxki, ado-trastuzumab emtansine, and sacituzumab govitecan-hziy.
HER2-Directed Therapy, Trastuzumab Deruxtecan, Approved for Metastatic NSCLCAugust 12th 2022
The FDA has approved trastuzumab deruxtecan for patients with HER2-mutated non–small cell lung cancer after the DESTINY-Lung02 results demonstrated a 57% overall response rate with the agent. The drug comes with warning for interstitial lung disease, neutropenia, and left ventricular dysfunction.
Capmatinib Snags Full FDA Approval for MET Exon 14 Skipping NSCLCAugust 11th 2022
The FDA has granted capmatinib regular approval for patients with metastatic non–small cell lung cancer (NSCLC) whose tumors have a mutation leading to MET exon 14 skipping. The drug comes with warning for pneumonitis, hepatotoxicity, and pancreatic toxicity.
ESMO Guideline on Liquid Biopsy Address Quality Standards for Clinical ImplementationJuly 27th 2022
In early-stage cancers, ctDNA has a role in screening, neoadjuvant monitoring, identification of molecular residual disease (MRD), molecular relapse monitoring, and early assessment of treatment response.
Nivolumab/Ipilimumab Efficacy in Clear Cell RCC May Be Tied to Certain Immune-Cell Related ParametersFebruary 22nd 2022
Patients with 4-1BB or LAG-3–expressing T cells at baseline, or a high proportion of PD-L1–expressing myeloid cells and plasmacytoid dendritic cells during boost cycles, may be more likely to benefit from the combination of nivolumab and ipilimumab.
Germline Testing for Lynch Syndrome: More Important Than EverOctober 4th 2020
With the emergence of several targeted treatments that have shown efficacy in individuals with germline pathogenic variants, specifically in DNA mismatch repair, the need for germline genetic testing has become even more pronounced.
Cancer and Genetic Testing: Expert Answers Common QuestionsAugust 2nd 2020
Genetic testing is more important now than ever before, as biomarker-driven cancer treatments continue to receive approval across many tumor types. While these personalized treatments are improving outcomes, navigating the landscape of genetic testing can leave patients with questions for their providers.
Biomarkers Predict Osteosarcoma Treatment ResponseFebruary 2nd 2020
The presence of the proteins p16 and p21 has shown to be predictive of treatment response in patients with osteosarcoma, a disease that previously had no identified biomarkers to indicate whether or not patients would benefit from therapy, explained C. Parker Gibbs, MD.
Expert Talks Liquid Biopsies, Molecular Testing in Lung CancerJanuary 3rd 2020
Not all patients with advanced non–small cell lung cancer (NSCLC) are recommended for genomic testing when treated in a community setting, and are therefore not being appropriately tested for potential molecular drivers of their disease, explained Nathan Pennell, MD, PhD.